Imagine a targeted approach to bladder cancer that spares healthy cells while delivering chemotherapy directly to cancerous ones, offering hope for patients with advanced stages of the disease.

The MarketWatch News Department was not involved in the creation of this content. -- ZUSDURI (formerly known as UGN-102) is a localized medication designed for potent tumor ablation delivered by ...

Disease-free survival rate of 58% at 12 months (primary endpoint) and 52% at 24 months Cystectomy avoidance rate of 82% at 36 months—unmatched by any product in the field to date Disease-specific ...

With iQ+ Bladder, Butterfly expands outside its core point-of-care ultrasound market to better serve the bladder scanning market with its proprietary Ultrasound-on-Chip™ technology. The bundled ...

As the researchers behind Pfizer and Astellas' Padcev and Merck's Keytruda have taken victory laps on the heels of the ...

Dr. Walker is a firm believer in the use of natural supplements to improve the body's defenses to help win the battle against bladder Infections. Chronic recurrent bladder infections can be a ...

People with type 1 diabetes (previously called juvenile diabetes) are 4.29 times more likely to develop bladder cancer, ...

- If approved, enfortumab vedotin in combination with pembrolizumab will be the first and only treatment to offer an alternative to platinum-containing chemotherapy, the current standard of care for ...

Researchers say a new drug-delivery implant could help patients with hard-to-treat bladder cancer avoid losing their bladders — and stay cancer-free for years.

Detailed price information for Theralase Technologies Inc (TLT-X) from The Globe and Mail including charting and trades.

BOULDER, Colo. — Deion Sanders was laughing when he said it, but it wasn't a joke. "I depend on Depend," Sanders said, referencing the adult underwear brand for people struggling with incontinence. "I ...